Heart failure & cardiomyopathies
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure
Main finding · New-onset cancer, malesResult — go to the resultHazard ratio 1.89 95% CI 1.32–2.71Authors' conclusion
Gal-3, a marker of fibrosis, is associated with new-onset cancer and new-onset HF in males, but not in females.
Study context
- Population
- Healthy participants of the PREVEND study (50% males)50% males
- Participants
- 5,786 participants
- Exposure
- Increase in gal-3 vs no relevant increase over 4 years
- Outcome
- New-onset cancer and new-onset HF
- Follow-up
- Total 11.5 years
Methodological detailssex-stratified analysis
- Sex-stratified analysis
Main finding
New-onset cancer, males
Hazard ratio
1.89
95% CI 1.32–2.71
P < 0.001
Increase in gal-3 (≥50%)vs no relevant increase over 4 years
HR 1.89 (95% CI 1.32–2.71); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure. JACC CardioOncol. Published 11 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →